Tisch MSRCNY Hosts 23rd Annual MS Patient Education Symposium
MS Continuum: Where we were, Where we are & Where we are going
Sunday, March 19th, 2023 9:30 am to 1:00 pm
New York Hilton Midtown: 1335 Avenue of the...By choosing Tisch MSRCNY as your charitable recipient on Amazon Smile, Amazon will donate to our laboratory at no additional cost to you.
...
The IMSMP will be closed on Monday, January 16, 2023, in observance of Martin Luther King Jr. Day.
The FDA recently approved ublituximab (BriumviTM) for the treatment of relapsing forms of Multiple Sclerosis. Ublituximab is a member of the anti-B cell (anti-CD20 monoclonal antibody) family of drugs, which includes rituximab (RituxanTM), ocrelizumab (OcrevusTM), and ofatumumab (KesimptaTM). The primary difference between these drugs is how they are administered and the length of time required to safely administer the medication. Ublituximab, like...
moreTisch MSRCNY will be hosting its 23rd annual patient symposium.
... moreThe IMSMP wishes everyone a joyous holiday season!
We will be closed on Friday, December 23rd, and we will reopen on Tuesday, December 27th at 9:00 AM.
...
moreBack by popular demand…The Tisch MSRCNY will be hosting its 23rd annual patient symposium.
... moreBecause you deserve only the best in MS healthcare. Experience the difference.
Join our mailing list today! Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.
* We don’t share your information with anyone.
